Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Optimizing non-viral gene delivery requires screening across delivery systems, DNA payload conformations, and expression formats simultaneously. Switching from standard double-stranded DNA to single-stranded formats encoding circular RNA can generate immune-quiet vectors that exhibit high stability and prolonged in vivo expression without requiring viral capsids.

Related Insights

The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.

In vivo CAR applications face a difficult trade-off between ultra-short LNP-mRNA expression and permanently integrating lentiviruses that carry oncogenic risks. Circular RNA provides a transient three-to-six-month expression window that is durable enough to clear solid and liquid tumors while remaining completely re-dosable and reversible.

AAV gene therapies frequently require dangerously high doses because baseline expression is low. Boosting expression over 200-fold using circular RNA cassettes allows developers to cut viral dosing proportionally, dramatically reducing manufacturing costs, resolving capsid-related toxicities, and potentially reviving assets abandoned due to insufficient potency.

Contrary to common belief, manufacturing costs for gene therapies are becoming manageable and approaching those of biologics. The real bottleneck preventing their use in broader diseases is the need to optimize the 'clunky' delivery vectors for better targeting and safety.

Beyond clinical benefits like re-dosability, NGene's non-viral approach offers significant commercial advantages. The therapy is more cost-efficient to manufacture at scale and avoids the complex handling protocols of viral vectors. This design choice directly addresses major logistical and financial hurdles in the gene therapy market.

Sonothera's method physically deposits genetic payloads into cells through transient pores, bypassing the endosomal pathways used by viruses and LNPs. This avoids triggering innate immune sensors like CGAS and STING. This “immune stealth” approach is key to the platform's favorable safety profile and its ability to be repeatedly administered.

The DDX platform uses a proprietary sugar to deliver large genetic payloads, unlike size-constrained viral vectors. This non-viral approach avoids immunogenicity, allowing for redosing, and relies on simple, available ingredients, which significantly simplifies manufacturing and lowers cost of goods.

Create Medicines chose LNP-delivered RNA for its in vivo platform to give physicians control. Unlike permanent lentiviral approaches, repeatable dosing allows for adapting to tumor antigen escape and managing durability and safety over time. This flexibility is a core strategic advantage for complex diseases like solid tumors.

Standard molecular biology typically seeks stronger promoters to increase RNA transcription rates, but slowing decay accomplishes the same endpoint. Because circular RNA lacks vulnerable free ends, it resists typical intracellular turnover machinery and accumulates continuously to achieve far higher steady-state expression levels than linear mRNA.

Beyond transient RNA, Create has developed a unique retrotransposon based on the human Line-1 element. This technology allows for stable, scarless gene delivery using only RNA, providing an option for durable expression (e.g., for CD19 CAR-T) alongside their transient approaches, creating a highly versatile platform.